Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.33 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17490456 | 0.92 | SCN9A (0.32) | SCN9AHTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL20380616 | 0.86 | SCN9A (0.36) | FFAR1PPARDFFAR4P2RX7SCN9A | |
| SCHEMBL20380572 | 0.83 | SCN9A (0.37) | FFAR1PPARDFFAR4SCN9APDE10A | |
| SCHEMBL26277391 | 0.82 | RIPK1 (0.39) | FFAR1PPARDPDE10AHTR2AHTR2C | |
| SCHEMBL15235148 | 0.81 | FFAR1 (0.36) | FFAR1PPARDFFAR4P2RX7SCN9A | |
| SCHEMBL26277379 | 0.80 | HTR2A (0.39) | FFAR1PPARDPDE10AHTR2AHTR2C | |
| SCHEMBL26277357 | 0.78 | RIPK1 (0.37) | FFAR1PPARDPDE10AHTR2AHTR2C | |
| SCHEMBL16871478 | 0.78 | RIPK1 (0.37) | FFAR1PPARDPDE10AHTR2AHTR2C | |
| SCHEMBL17355585 | 0.77 | SCN9A (0.32) | SCN9AHTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL16769006 | 0.77 | HTR2A (0.36) | FFAR1PPARDPDE10AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441161-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160032187-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160032187-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, OCIAD2, PIEZO1 | FFAR1 1307/4885PPARD 4628/4885FFAR4 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.